番茄社区app

Hormone receptor-positive patients with high TMB may fare well with immunotherapy

Yuan Yuan, MD, discusses the need for evidence-based answers in 2024

Lajos Pusztai reviews the two "potentially paradigm-shifting trials"

But sequencing of ADCs such as datopotamab deruxtecan remains an unanswered question

Virginia Kaklamani, MD, discusses this year's sessions of interest and looks ahead to next year

Jason Mouabbi, MD discusses the most exciting news out of SABCS 2022

Trial participation not significantly different for patients opting for telemedicine

Virginia Kaklamani, MD, makes some hopeful predictions

Sylvia Adams, MD, shares her view on the future of treatment